Serine/threonine protein phosphatase 6 modulates the radiation sensitivity of glioblastoma. by Shen, Y et al.
UCLA
UCLA Previously Published Works
Title
Serine/threonine protein phosphatase 6 modulates the radiation sensitivity of 
glioblastoma.
Permalink
https://escholarship.org/uc/item/9dv4260n
Journal
Cell death & disease, 2(12)
ISSN
2041-4889
Authors
Shen, Y
Wang, Y
Sheng, K
et al.
Publication Date
2011
DOI
10.1038/cddis.2011.126
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Serine/threonine protein phosphatase 6 modulates the
radiation sensitivity of glioblastoma
Y Shen1,5, Y Wang1,5, K Sheng2, X Fei3, Q Guo3, J Larner4, X Kong3, Y Qiu*,3 and J Mi*,1,2
Increasing the sensitivity of glioblastoma cells to radiation is a promising approach to improve survival in patients with
glioblastoma multiforme (GBM). This study aims to determine if serine/threonine phosphatase (protein phosphatase 6 (PP6)) is a
molecular target for GBM radiosensitization treatment. The GBM orthotopic xenograft mice model was used in this study. Our
data demonstrated that the protein level of PP6 catalytic subunit (PP6c) was upregulated in the GBM tissue from about 50%
patients compared with the surrounding tissue or control tissue. Both the in vitro survival fraction of GBM cells and the patient
survival time were highly correlated or inversely correlated with PP6c expression (R2¼ 0.755 and0.707, respectively). We also
found that siRNA knockdown of PP6c reduced DNA-dependent protein kinase (DNA-PK) activity in three different GBM cell lines,
increasing their sensitivity to radiation. In the orthotopic mice model, the overexpression of PP6c in GBM U87 cells attenuated
the effect of radiation treatment, and reduced the survival time of mice compared with the control mice, while the PP6c knocking-
down improved the effect of radiation treatment, and increased the survival time of mice. These findings demonstrate that PP6
regulates the sensitivity of GBM cells to radiation, and suggest small molecules disrupting or inhibiting PP6 association with
DNA-PK is a potential radiosensitizer for GBM.
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Glioblastoma multiforme (GBM) is one of the most difficult
primary cancers to treat and usually rapidly fatal. Owing to the
unique structure and function of the brain, radiation therapy
is a conventional treatment for the GBM patient along with
surgery. Although radiation doubles the survival time of GBM
patients, GBM cells are highly resistant to radiation and the
tumors are almost never completely eradicated by it. There-
fore, increasing the radiation sensitivity of GBM cells is a
promising approach to improve GBM patients’ survival.
It is well known that ionizing radiation (IR) induces DNA
double-strand breaks (DSBs), which is the most severe type
of DNA damage. The predominant mechanism of DSB repair
is non-homologous end-joining, in which DNA-dependent
protein kinase (DNA-PK) plays a central role. DNA-PK is
composed of a catalytic subunit (DNA-PKcs) and two Ku
heterodimers, which act as regulatory subunits.1 It has been
shown that DNA-PKcs/ mice are hypersensitive to IR and
that high levels of unrepaired DSBs were observed in DNA-
PKcs/ mice after exposure to other forms of genotoxic
agents.2 Numerous studies including ours have shown that
the DNA-PK activity was increased in radiation-resistant GBM
cells.3 Chemical inhibitors of DNA-PK, such as NU7441 and
LY294006, show strong sensitization of several tumor cell
lines to radiation.4–6 These observations suggest that
molecules that inhibit DNA-PK activity may be able to improve
the outcome of radiation therapy. However, DNA-PKcs is a
ubiquitously expressed protein; there is no significant differ-
ence in protein level between normal tissue and tumor based
on the data from TCGA and our group (data not shown).
Therefore, DNA-PKcs itself is not a good molecule target for
radiosensitization treatment, as the drugs targeting tumor
cells also damage normal tissue, and result in side effects.We
have previously found the protein phosphatase 6 (PP6)
regulates DNA-PK activity in GBM cells.7 If PP6 is differen-
tially expressed in radiation-resistant GBM cells compared
with radiation-sensitive GBM cells, PP6 could be a potential
target for radiosensitization treatment.
PP6 is a Ser/Thr protein phosphatase classified as a type
2A phosphatase family member based on its sequence
homology to the catalytic subunit of PP2A.8 PP6 is sensitive
to active site inhibitors such as okadaic acid, microcystin and
calyculin A.9 The holoenzyme of PP6 is functionally distinct
from other type 2A phosphatases and conserved in evolu-
tion.10 The holoenzyme of PP6 is proposed to be a
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heterotrimer that consists of a catalytic subunit (PP6c), a Sit4-
associated protein subunit and an ankyrin repeat subunit
(ARS). PP6 plays a role in the regulation of NFkB signaling11
and IR-induced phosphorylation of histone H2AX.12 Our
recently published study along with the study from another
group have shown that PP6 is a component of the DNA-PK
complex; siRNA knockdown of either PP6R1 or PP6c reduces
IR-induced DNA-PK activation and increases the sensitivity of
glioblastoma M059K cells to radiation.7,12 However, it is not
clear as to whether PP6 is a potential therapeutic target for
radiosensitization of GBM cells in vivo.
In this study, we show that PP6c is upregulated in the
glioblastoma (grade IV) tissues of 44.7% patients, and PP6c
protein levels correlate with patient survival time. The
lentivirus-mediated PP6c overexpression in GBM U87 cells
attenuated the effect of radiation treatment, and reduced the
mouse survival time compared to control mice in the
orthotopic mice model. While, knocking-down PP6c improved
the effect of radiation treatment and increased the mouse
survival time. These observations suggest that PP6 might be
a therapeutic target for radiosensitization of tumor cells in
GBM patients and that PP6 protein level could be a potential
biomarker to predict GBM prognosis.
Results
PP6c expression is increased in glioblastoma tissue
from patients and its protein level is inversely correlated
with patient survival time. To determine if the PP6c protein
is differentially upregulated in glioblastoma tissue and its
correlationship with patient survival time, the immuno-
fluorescence staining on the cryosections of glioblastoma
tissues was performed and the patient survival time was
recorded. In all, 38 patients were recruited in this study.
In total, 10 consecutive sections of glioblastoma tissuewere
analyzed for each patient. All staining procedures and the
microscopy settings were identically performed according to
the protocol. Representative PP6c images among sequential
imaging from the consecutive sections were selected for
further semiquantification analysis by the densitometry.
Regarding the subtotal surgical removal and the unique
structure of brain, non-tumor glial tissue from epilepsy
patients was taken as an additional control in this study
besides para-tumor tissues. The fluorescence density of
PP6c in both the non-tumor glial tissue from epilepsy patient
and the tumor-surrounding tissue was undetectable as a
background (Figure 1a), which indicates that the PP6c
expression level is low in normal glial cells. However, the
GBM sections from about half of patients (17/38; 44.7%)
showed increased PP6c protein expression compared with
non-tumor glial tissue or tumor-surrounding tissue. In fact, the
average fluorescence density of PP6c in the GBM sections
was 50% brighter than that in non-tumor glial sections or
tumor-surrounding tissue. Moreover, according to the micro-
array data fromGBM patients in the Cancer Genomics Center
of the NIH (https://www.oncomine.org/resource/main.html),
in which the expression profile of PP6c in 237 tissue samples
was compared with that in the normal brain tissue, the
expression of PP6c is upregulated in GBM tissues compared
with normal glial tissue (Figure 1b; Po0.05). This result is
consistent with our immunostaining data (Figure 1a) and data
from another group.13 DNA-PKcs protein levels were also
analyzed in these tissues, and no significant changes in DNA-
PKcs expression was observed between GBM tissue and
normal tissue (data not shown).
On the basis of the ratio of the fluorescence density of PP6c
staining in the GBM samples to that in the control tissue, the
GBM samples were classified into four groups: the (þ ) group
means the fluorescence density increase of PP6c staining
is o20%; the (þ þ ) group means this increase is Z20%
ando40%; the (þ þ þ ) group means the increase isZ40%
and o60%; and the (þ þ þ þ ) group means the increase
is460%. The rows from the 3rd to the 6th of Figure 1a show
representative pictures of tissue sections at each level of
fluorescence density. According to our analysis, the 65.8% of
patients (25/38) were classified into (þþ ) or (þþþ ) groups,
only the 10% of patients (4/38) have strong PP6c staining and
the other 9% patients have weak or low PP6c staining. On the
basis of the above semiquantitative classification of PP6c
protein levels, the correlations between PP6c protein levels
and patient survival time were analyzed. As shown in
Figure 1c, patient survival timewas highly inversely correlated
with PP6c protein levels (R2¼ 0.707, Po0.001). Patients with
high PP6c protein expression tends to have shorter survival
time. Moreover, although the patient age is differed from 20 to
65 years old, the data did not show any correlation between
age and survival time (R2¼ 0.0078, P¼ 0.5959). This
observation suggests that the overexpression of PP6c in
glioblastoma tissues can be taken as a biomarker for
prognosis.
PP6c protein level correlates with radiation resistance of
glioblastoma cells. To further determine whether PP6 is a
potential target for radiosensitization, 10 GBM cell lines,
including U87, U251, A172, U138, U118, T98G, M059K, Ln-
229, Ln-18 and M059J, were used to determine the
correlation between PP6c expression levels and radiation
resistance. PP6c expression level was detected in these 10
GBM cell lines by real-time PCR. The PP6c expression level
was normalized to that of GAPDH. The survival fractions
after radiation treatment were measured by the clonogenic
assay. The data showed that PP6c expression levels were
highly correlated with the survival fraction of glioblastoma
cells with 5Gy radiation treatment, and the correlation
coefficient (R2) is 0.755 (Figure 2a).
T98G, A172 and U251 were three representative glioblas-
toma cell lines with significant difference in radiosensitivity,
which were selected from the 10 GBM cell lines for further
study. Figure 2b shows western blots of these three cell lines
1 h after treatment with or without radiation (5Gy). The protein
levels of PP6c were analyzed using densitometry (Image J
software, NIH, Bethesda, MD, USA), and the data were
normalized to the density of Ku80 and b-tubulin. Semiquanti-
fication of the immunoblots showed that the protein levels of
PP6c were highest in T98G cells, followed by A172 and U251
cells (Figure 2c). Interestingly, DNA-PKcs was found to be
cleaved in radiation-treated U251 cells, which were most
sensitive to radiation among these 10 GBM cell lines
(Figure 2b); however, the total protein level of DNA-PKcs
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Figure 1 The expression of PP6 catalytic subunit (PP6c) is increased in glioblastoma tissues from patients and its protein levels inversely correlate with patient survival
time. (a) The 380 sections from 38 glioblastoma multiforme (GBM) patients (10 slides each patient) were analyzed. The figure rows show representative pictures of non-tumor
epilepsy brain section (the 1st row), para-tumor tissue (the 2nd row) and GBM sections (3rd–6th rows). The left panels show PP6c staining (green), the middle panels show
40,6-diamidino-2-phenylindole (DAPI) staining (blue) and the right panels show merged images. The quantification analysis of PP6c fluorescence density (FD) was carried out.
The patient samples were classified into four groups ranging from low to high expression (þ , FDo20%; þþ , 20%rFDo40%; þþþ , 40%rFDo60%; þþþþ ,
FDZ60%); the scale bar indicates 2 nm. (b) The expression microarray data of GBM tissue downloaded from the public database of the Cancer Genomic Center (TCGA, NIH)
was statistically analyzed by Student’s t-test. The bar represents log2 copy number units of normal brain tissue or GBM tissue (median±S.D.). (c) The dose–effect relationship
between PP6c protein levels and the survival time (months) of GBM patients was analyzed by the Mann–Whitney U-test. The coefficient of determination (R2) in the linear
regression model is indicated
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was not found to be dramatically increased, which was
consistent with the previous microarray data.
In addition, the radiosensitivity of these cells was deter-
mined by the clonogenic assays.14 Approximately 60% of
T98G cells survived after irradiation with 5Gy compared to
only 8.86% of A172 cells and 6.87% of U251 cells (Figure 2d).
The plating efficiencies were about 40% without radiation
treatment in these experiments. Apparently, the T98G cells
were most resistant to radiation among the three glioblastoma
cell lines, which was consistent with the data from another
group.3 These observations suggest a relationship between
PP6c expression levels and radiation resistance.
IR-induced DNA-PK activity is correlated with radiation
resistance in glioblastoma cells. To determine whether
DNA-PK activity has a dose–effect relationship with the
radiosensitivity of glioblastoma cells, the three representative
GBM cell lines, T98G, A172 and U251, were used for this
study. The DNA-PK activities in three cell lines were
measured 30min post-IR, with or without Nu7026, a DNA-
PK-specific inhibitor. As shown in Figure 3a, IR-induced
DNA-PK activity was 2.3 times higher in T98G cells than in
A172 cells, and 3 times higher than in U251 cells. Nu7026
abrogated the effect of IR on DNA-PK activity, which is close
to the level of that in the untreated cells. The correlation
Figure 2 PP6 catalytic subunit (PP6c) protein levels correlate with radiation resistance of glioblastoma cells. (a) The dose–response relationship between PP6 protein
levels and the radiosensitivity of glioblastoma cells was analyzed by the Mann–Whitney U-test. The coefficient of determination (R2) in the linear regression model is indicated.
(b) T98G, A172 and U251 cells were left untreated or irradiated with 5 Gy. At 1 h after irradiation, cells were lysed and subjected to immunoblot analysis. The protein levels of
DNA-PK catalytic subunit (DNA-PKcs) and PP6c in these cells were detected. (c) The protein levels of PP6c were quantified by densitometry analysis using the Image J
software and the reading was normalized to internal controls of Ku86 and b-tubulin. The error bars represent the S.D. of the means of three independent experiments. The
statistical significance of the differences of the PP6c amount between the different cell lines was determined by Student’s t-test (*Po0.001; #Po0.05). (d) The representative
images from clonogenic assay. (e) In all, 100 T98G, A172 or U251 cells treated with the indicated doses of radiation were seeded in a 100 mm dish. Colony numbers were
normalized to the untreated controls of each cell line. The error bars represent the S.D. of the means of three independent experiments
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between DNA-PK activity and radiation resistance in T98G,
A172 and U251 cells was determined by the Mann–Whitney
U-test. Similar to PP6c protein levels, DNA-PK activity was
highly correlated (R2¼ 0.931) with the survival fraction of the
glioblastoma cells (Figure 3b).
Moreover, the endogenous DNA-PK activity was also
measured through detecting the phosphorylation of endogen-
ous replication protein A, whose 32-kDa subunit (RPA32) is
differentially phosphorylated by three phosphatidylinositol-3-
kinases (ataxia telangiectasia mutated (ATM), ATM-Rad3
related, DNA-PK) in response to different DNA-damaging
agents. DNA-PK is the primary kinase responsible for RPA32
phosphorylation in response to camptothecin (CPT) treat-
ment,15–17 and thus CPT-induced phosphorylation of RPA32
is an indirect measure of DNA-PK activity. Phosphorylation of
RPA32 is observed in immunoblots as the appearance of a
band of reduced mobility relative to the parent RPA32 band,
and this new band can be detected by an RPA32 Ser 4/Ser 8
phospho-specific antibody. CPT treatment induced RPA32
phosphorylation in all three glioblastoma cell lines (Figure 3c),
and the DNA-PK specific inhibitor Nu7026 attenuated this
phosphorylation (upper bands) of the endogenous RPA32
(Figure 3c). On the basis of our calculation, the ratio of
phosphorylated RPA32 to unphosphorylated RPA32 in the
radiation-treated T98G cells was 2 times more than that in IR
plus Nu7026-treated T98G cells, which in A172 cells or U251
cells was 1.32 or 1.26 times, respectively (Figure 3d). Using
statistical correlationship analysis, the change in CPT-
stimulated phosphorylation of RPA32 was highly correlated
(R2¼ 0.931) with the survival fraction of the glioblastoma cells
(data not shown). These data further demonstrated the DNA-
PK activity was distinct in the different GBM cells.
Taken together, these observations suggest a strong
relationship between DNA-PK activity and radiation resis-
tance.
siRNA knockdown of PP6c reduces DNA-PK activity and
increases the sensitivity of glioblastoma cells to
radiation. To further verify whether PP6 regulates
radiosensitivity of GBM cells through DNA-PK, it was
necessary to assess the effects of PP6 on DNA-PK activity
and radiosensitivity in these cells. To address this question,
Figure 3 Ionizing radiation (IR)-induced DNA-dependent protein kinase (DNA-PK) activity is correlated with radiation resistance in glioblastoma cells. (a) T98G, A172 and
U251 cells were treated with Nu7026 (10 mM) 30 min before irradiation (5 Gy) or without radiation. At 1 h post-irradiation, the nuclear fractions from these cells were isolated,
and then subjected to a DNA-PK kinase assay using a specific peptide as substrate (*Po0.001; #,**Po0.05). (b) The dose–response relationship between DNA-PK activity
and the survival fraction of glioblastoma cells was analyzed by the Mann–Whitney U-test. The coefficient of determination (R2) in the linear regression model is indicated.
(c) T98G, A172 and U251 cells were treated with Nu7026 (10 mM) for 30 min before camptothecin (CPT) treatment. At 3 h post-irradiation, whole-cell lysates were subjected
to immunoblotting for total or phospho-specific RPA32 detection using RPA32 antibody (top row). b-Actin was used as a loading control. (d) Phosphorylated and
unphosphorylated RPA32 were quantified by the Image J software, and the readings were normalized to the internal control of b-tubulin. The error bars represent the S.D. of
the means of three independent experiments. The statistical significance of the differences between the ratio of phosphorylated to unphosphorylated RPA32 in each cell line
was determined by Student’s t-test (*Po0.001; #,**Po0.05)
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we transfected our three glioblastoma cell lines, T98G, A172
and U251, with siRNA to specifically knock down PP6c. The
activity of DNA-PK was analyzed in nuclear extracts using an
in vitro kinase assay with a specific peptide substrate. In the
absence of IR treatment, siRNA knockdown of PP6c only
slightly affected the basal activity of DNA-PK (Figure 4a; light
gray bars versus empty bars). The knocking-down efficiency
of PP6c was determined by western blot (Figure 4a).
However, post-IR DNA-PK activity in all three cell lines
increased 2- to 4.5-fold over basal activity levels, while the
siRNA knockdown of PP6c in all three cell lines markedly
reduced the IR-induced DNA-PK activity under similar
conditions (Figure 4a; dark gray bars versus middle gray
bars).
In the mean time, the PP6c were stably overexpressed in
U251 cells or stably knocked down in T98G cells by the
lentivirus-mediated infection, as the endogenous PP6c
protein level in the U251 cells was much lower than that in
the T98G cells. After the CPT treatment, the CPT-induced
RPA32 phosphorylation in PP6c downregulated T98G cells
Figure 4 Small interfering RNA (siRNA) knockdown of PP6 catalytic subunit (PP6c) reduces DNA-dependent protein kinase (DNA-PK) kinase activity in three different
glioblastoma cell line and increase the sensitivity of glioblastoma cells to radiation. (a) T98G, A172 and U251 cells were transfected with PP6c-specific siRNA or non-specific
siRNA. At 48 h after transfection, the cells were treated with 5 Gy radiation or sham radiation, and subjected to the DNA-PK kinase assay using a specific peptide as
substrate.30,31 The data were normalized to the number of non-irradiated and non-PP6c siRNA-transfected T98G cells. The error bars represent the S.D. of the means of three
independent experiments. The statistical significance of the differences between the DNA-PK activity in the irradiated PP6c siRNA-treated or control siRNA-treated cells was
determined by Student’s t-test (*, #, **Po0.001). The western blotting showed the siRNA knocking-down efficiency of PP6c in T98G, A172 and U251 cells. (b) The T98G cells
infected by the lentivirus containing PP6c siRNAs or control siRNA were treated with camptothecin (CPT)- and/or DNA-PK-specific inhibitor Nu7026, the Ser 4/8
phosphorylation of RPA32 were detected by western blot and the bottom panel shows PP6c knocking-down efficiency in stable T98G cells. (c) The U251 cells infected by the
lentivirus containing PP6c coding sequence or control siRNA were treated with CPT- and/or DNA-PK-specific inhibitor Nu7026, the Ser 4/8 phosphorylation of RPA32 were
detected by western blot and the bottom panel shows PP6c protein level in stable U251 cells. (d) T98G, A172 and U251 cells were transfected with PP6c-specific siRNA or
nonspecific siRNA and then treated with the indicated dose of radiation. All colony numbers were normalized to the untreated control of each cell line. The error bars represent
the S.D. of the means of three independent experiments
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were significantly lower than that in control T98G cells
(Figure 4b), while the CPT-induced RPA32 phosphorylation
in PP6c overexpressed U251 cells were obviously higher than
that in control U251 cells (Figure 4c). These observations
indicated that the DNA-PK activity, at least the CPT-induced
DNA-PK activation, was regulated by PP6. These data
suggest that the DNA-PK activity in radiation-resistant
glioblastoma cells can be modulated through the regulation
of PP6, and either the downregulation of PP6c or the inhibition
of DNA-PK activity can improve the radiation resistance of
these cells.
To further test whether PP6 regulates the radiosensitivity of
these three glioblastoma cells, clonogenic assays were
performed in T98G, A172 and U251 cells transfected with
PP6c-specific siRNA or control siRNA. The plating efficien-
cies were 20–30% after transfection of siRNA in these
experiments. The siRNA knockdown of PP6c significantly
increased the sensitivity of these glioblastoma cells to
radiation compared with the nonspecific siRNA-transfected
cells (Figure 4d; open symbols versus filled symbols). These
observations demonstrated that PP6 does regulate the GBM
radiation sensitivity, and suggest that PP6 is a candidate
molecular target for GBM radiosensitization.
PP6c knocking-down improves the radiation therapeutic
efficacy on the mice bearing orthotopic xenografted
glioblastoma. The glioblastoma U87 cells overexpressing
PP6c or knocking-down PP6c were intracranially injected
into the right caudate nucleus of the athymic nude mice
(1 106 each), with the aid of a small animal stereotactic
frame, and 72 mice were injected. The U87 cells infected with
empty viruses were taken as control. At 10 days after
injection, mice bearing tumor (62 mice) were randomly
divided into two groups according to the MRI imaging,
including IR and non-IR irradiation. Each group contains
control, overexpression and knock-down subgroup (10 mice
in each subgroup). The 6Gy of total radiation were
administered over three times in 1 week, and the schedule
was described in Materials and methods. The survival time of
each mouse was recorded, and all survival times in each
group were analyzed using Kaplan–Meier method. Our
results showed that the radiation treatment prolonged the
mice survival time in all group. With radiation treatment, the
mice in the PP6c knocking-down group survived longest (53
days, median survival time) among the mice in three groups;
the mice survival time in the control group and the PP6c
overexpression group were 42.5 and 32.5 days, respectively
(Figure 5a). Although without radiation treatment the mice
survival time in the PP6c knocking-down group was longer
than that in other groups too, the radiation enhancement
of survival time in the PP6c knocking-down group was
26.9%, much higher than that in the control group and
the PP6c overexpression group, which was 14.2 and
7.3%, respectively. The differences were found to be
statistically significant (Po0.001).
On the basis of the MRI image of tumors at the 9th day after
intracranial injection, the tumor size in each group had some
but not significant difference (representative pictures shown in
the top row of Figure 5b). After radiation treatment, the tumor
size in the PP6c knocking-down group at the 21st day did not
show significant growth compared to the tumor size of the
same mouse at the 9th day (representative pictures shown in
the right panels of Figure 5b). As same as our expectation, the
tumor sizes in the PP6c overexpression group at the 21st day
were obviously larger than the tumor size of the same mouse
at the 9th day (representative images as shown in the middle
panels of Figure 5b). The average volumes of tumor in each
group have been shown in the graph of Figure 5b; the tumor
sizes shrank more (54.3%) in the PP6c knocking-down group
than that in the control group (38.9%) and PP6c over-
expressing group (16.3%), although the tumor volumes are
different in each group. The fluorescence immunostaining of
PP6c protein level in GBM tissue were shown in Figure 5c.
Discussion
There is ample evidence in the literature that cellular
phosphatase activity and radiosensitivity are functionally
related. Nakamura et al.18 reported that the serine/threonine
protein phosphatase inhibitor calyculin A enhanced cell killing
when cells were treated 30min before X-ray irradiation.
Recently, Chapman’s group reported that HT-29 human
colon carcinoma cells treated with inhibitors of protein
phosphatases 1 and 2 were significantly more sensitive to
radiation than untreated cells.19,20 However, these chemicals
are highly cytotoxic to all cells, including normal cells, and how
to increase the sensitivity of tumor cells to radiation while
minimizing the side effects caused by a radiosensitizing drug
is still challenging to radiobiologists. Owing to the unique
structure and function of the brain, subtotal surgery, one of
two major conventional treatments, cannot completely re-
move GBM cells – even when combined with radiotherapy,
the efficacy of which is never satisfactory owing to the high
resistance of GBM cells to radiation. The deficiency of these
methods results in worse prognosis of GBM patients. Thus,
finding a way to enhance the efficacy of radiotherapy is critical
to the survival of GBM patients.
Our data demonstrated that PP6 regulated IR-inducedDNA-
PK activation, and the DNA-PK activity as well as the PP6c
protein levels inversely correlated with the radiosensitivity in
GBM cells. Interestingly, the protein level of DNA-PKcs was
not upregulated in the cells with high expression of PP6c
based on the western blot and immunofluorescence staining.
These observations indicate that PP6 regulates the radio-
sensitivity of GBM cells by modulating DNA-PK activity rather
than increasing DNA-PKcs protein expression. The impor-
tance of DNA-PK in radiosensitivity regulation and DNA repair
is well known.1,2,21–23 Although several chemical compounds
directly targeting DNA-PK activity as a radiosensitizer are
currently under development, exploring a more specific
molecular target in GBM cells is necessary for more efficacy
and less side effects because of the importance of DNA-PK
function in normal cells. In this study, our in vitro and in vivo
data suggest that PP6c is a promising biomarker for GBM
prognosis and may play a critical role in the progression of
GBM, although the mechanism by which PP6c expression is
upregulated in GBM cells is still unknown. Moreover, we noted
that the PP6c is not equally expressed in all GBM tissues, even
in the same GBM tissue, which suggests that these GBM cells
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overexpressing PP6c acquire the extra capability of radiation
resistance.
Furthermore, our in vivo data have shown that the radiation
enhancement of survival time in the PP6c knocking-down
groups are highest (26.9%) compared with the PP6c over-
expression group (7.3%) and the control group (14.2%); the
difference between the control group and either PP6c knock-
ing-down group or PP6c overexpression group has statistical
significance (Po0.001). The previous study shows that
DNA-PKcs is inactivated by phosphorylation at Thr 3950,
and thus PP6c overexpression possibly enhances the IR-
induced DNA-PK activation through dephosphorylation of
Thr 3950,24 which is one possible mechanism by which
PP6c knockdown increases radiation sensitivity of GBM cells.
In addition, PP6 is involved in a diversity of cellular function,
including gene transcription, cell-cycle progression and
apoptosis,25,26 all of which would influence tumor growth,
and PP6c knockdown may affect tumor growth through
regulating these progresses. These observations suggest
that PP6 not only regulates the sensitivity of GBM cells
to radiation, but also affects the glioblastoma growth
without radiation, and both effects will benefit the GBM
patients.
This study opens up new avenues for radiosensitization in
that molecules inhibiting PP6 activity or disrupting PP6
association with DNA-PK may improve the sensitivity of GBM
cells to radiation, although the safety of PP6 inhibitor or
molecules disrupting PP6/DNA-PK association has not been
tested as yet. Hepatocyte growth factor (HGF)/Met receptor is
another important protein kinase involved in radiation resis-
tance and cell proliferation. The Wang group reported that Met
protected endothelial cells against radiation-induced da-
mage,27 and PP2A, a PP6 family member, is a critical protein
phosphatase regulatingMet activity through phosphorylation of
Ser985.28 It is unknown if PP6 regulates GBM radiosensitivity
through the HGF receptor as DNA-PK may not be the only
downstream target for PP6-regulated radiosensitization.Owing
to the large number of growth factor signaling pathways PP6
participates in, we cannot at this point exclude other mechan-
isms mediating PP6-regulated radiosensitization.
In summary, we conclude that small molecules selectively
inhibiting PP6 activity are possible drugs for radiosensitization
Figure 5 Small interfering (siRNA) knockdown of PP6 catalytic subunit (PP6c) improves the radiation therapeutic efficacy on the mice bearing orthotopic xenografted
glioblastoma. (a) The mice were euthanized at the time of reaching a moribund condition, and all survival times in each group were analyzed using Kaplan–Meier method. This
experiment was independently repeated two times, six mice in each group at the start time point. The analyzed mice with radiation treatment in empty virus group (control),
PP6c knocking-down or PP6c overexpression group were 10, 11, 12, respectively, while the mice without radiation treatment in the control group, PP6c knocking-down or
PP6c overexpression group were 11, 11, 12, respectively. The radiation enhancements of survival time in each group were calculated by the formula: the survival time with
radiation divided by the survival time without radiation. The significance of radiation enhancement difference between control siRNA group and PP6c siRNA group were
analyzed by the w2 method (*Po0.001). (b) The representative tumor pictures from the PP6c overexpression, the PP6c knocking-down or the control group were captured by
magnetic resonance imaging (MRI) imaging at the 9th and 21st day with (þ IR (ionizing radiation)) or without radiation treatment (IR), and the tumor volumes were
calculated by the formula: 12 L S2 (L: maximum length; S: minimum length). (c) The representative PP6c immunofluorescence staining (red) in glioblastoma sections from
the PP6c overexpression, the PP6c knocking-down or the control group
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treatment.9 In addition, according to the observation that
DNA-PK mediates PP6c’s regulation of radiosensitivity, small
molecules disrupting the association of PP6 with DNA-PK
might be able to reduce selectively theDNA repair response to
IR and may thus be useful in enhancing the efficacy of
radiotherapy.
Materials and Methods
Patients and eligibility. This study was approved by the Ethical Review
Board of the Medical Faculty of the Shanghai Jiao-Tong University School of
Medicine. Patients from 20 to 65 years of age with newly diagnosed, histologically
confirmed GBM (World Health Organization grade IV astrocytoma) in the temporal
or frontal lobe were eligible for this study. In total, 38 patients were recruited in this
study. The patients were diagnosed and treated in the Shanghai Renji Hospital
between January 2006 and December 2007. These eligible patients received
standard radiotherapy (fractionated focal irradiation in daily fractions of 2 Gy given 5
days per week for 6 weeks) plus temozolomide (150 mg per m2 of body-surface area
per day, 5 days per week) within 1 month after surgery for subtotal removal. The
primary end point was patient death.
Cell lines and reagents. Glioblastoma T98G, U138 and U87 cells were
maintained in minimum essential medium (MEM; Invitrogen, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum (FBS; Invitrogen); U118, Ln-229, Ln-18,
A172 and U251 glioblastoma cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM; Invitrogen) supplemented with 10% FBS (Invitrogen); and M059K
and M059J glioblastoma cells were maintained in DMEM/F12 (1 : 1) (Invitrogen)
supplemented with 10% FBS (Invitrogen). All cells were maintained at 371C with 5%
CO2 and were in an exponential growth phase at the time of irradiation. The
following commercial antibodies were used: anti-DNA-PKcs pan-mouse
monoclonal, anti-Ku86 mouse monoclonal and anti-b-tubulin mouse monoclonal
(Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-PP6c rabbit polyclonal
(Bethyl Laboratories, Montgomery, TX, USA); anti-RPA32 mouse monoclonal and
b-actin mouse monoclonal (Sigma, St Louis, MO, USA), Alex 488-conjugated anti-
rabbit and Alex 594-conjugated anti-mouse secondary antibodies (Invitrogen) and
Vectashield Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA,
USA). The DNA-PK kinase assay kit was obtained from Promega Inc. (Madison, WI,
USA). All other reagents were purchased from Sigma.
The fluorescent immunostaining of GBMblocks from patients or
mice model. Dissected glioblastoma blocks were fixed with 4%
paraformaldehyde and embedded in paraffin, and 10 slices were generated from
each block. Non-tumor glial tissue from epilepsy patients or tumor-surrounding
tissue was used as a control. Followed by deparaffinization and hydration, the
paraffin-embedded sections were subjected to immunostaining and visualized by
fluorescence microscopy (Leica DM 2500, Shanghai, China). All staining
procedures and the microscopy settings were identically performed according to
the protocol. Images were captured and analyzed by the Openlab software
(Openlab, Shanghai, China).
The orthotopic GBM mice model. Congenitally athymic nude mice
(athymic Ncr-nu/nu), 5–6 weeks old (Charles River Laboratories, Wilmington, MA,
USA), were used in this study. The orthotopic tumor model for glioblastoma on a
protocol was approved by the Shanghai Jiao-Tong University Animal Care and Use
Committee. To prepare cells for transfer to the intracranial compartment, the
glioblastoma U87 cells either overexpressing or knocking-down PP6c, which were
validated by previous studies, or U87 cells infected with empty lentiviruses were
exponentially growing in culture dishes.
The cells at 90% confluent were trypsinized, and re-suspended in phosphate-
buffered saline (PBS). A cell suspension containing 1 106 cells per 5ml PBS was
used for one implantation into the striatal region of the athymic mouse brain. Under
deep isoflurane anesthesia, mice were placed in a small-animal stereotactic frame
(David Kopf Instrument, Tujunga, CA, USA). A sagittal incision was made through
the skin to expose the cranium, and a burr hole was made in the skull at 0.2 mm
anterior and 1.8 mm lateral (right) from the bregma using a small dental drill. At a
depth of 3 mm from the brain surface, 5 ml of cell suspension was injected. After
5 min, the needle was removed and the hole was sealed with bone wax (W810;
Johnson & Johnson International, Somerville, NJ, USA). The wound was sutured
immediately.
The mice were observed for body weight loss. They were killed by cervical
dislocation when they presented signs of neurological disorders or when their body
weight loss was 420% of their original weight, the time to this moment since
surgery is considered as ‘survival time’. Their brains were embedded into OCT
medium (Leica Inc., Wetzlar, Germany) and quickly frozen in801C after resection.
The GBM cryosections (CM1850; Leica Inc.) were processed for histopathological
analysis and fluorescence immunostaining of Alex 594-labeled PP6c. The
intragroup variation in the length of survival included standard deviation and 95%
confidence interval determinations were analyzed.
In vivo MRI imaging of tumor. GBM-bearing mice with or without radiation
were examined on day 9, 16 and 21 days post-tumor implantation to detect the growth of
the grafted tumor fragments. Tumor imaging in orthotopic mice model was performed with
a small animal coil on a High-Field GE Signa 3-Tesla clinical MR scanner (General
Electric, Waukesha, WI, USA), and images were obtained by using a standard
T1 protocol following gadolinium (Gd-DTPA, 100ml/20 g; Bayer Healthcare
Pharmaceuticals, Montville, NJ, USA) intraperitoneal injection 10 min before
examination. In enhanced scanning, scanning parameters was AxT1 FSE series –
scan plane: oblique; FOV: 5.0; phase FOV: 0.60; slice thickness: 1.0 mm; spacing:
0.0 mm; freq DIR: R/L; auto-TR: 600; and minimum TR: 60. Tumor sizes were measured,
and their volumes were calculated according to the following formula: (lengthwidth2)/2
using the Function Analysis software (General Electric); these results were subsequently
analyzed using the Image Pro-plus software (General Electric).29
Overexpression or siRNA knockdownof PP6c. Exponentially growing
T98G, A172 or U251 cells were infected with lentiviruses containing the coding DNA
sequence of PP6c (NM_001123355) or the specific siRNA (50 nM) against PP6c –
siRNA1: 50-AGACAGATAACACAGGTCT-30; siRNA2: TCGATCATGGTCTTCAA
AG. The preparation of lentiviruses were according to the protocol as described
previously.7 A nonspecific siRNA (sequence: 50-AAAUCUUCGAGACAUUCUGUU-30)
was used as a control. The other siRNA oligonucleotides used in this study were
purchased from Dharmacon (Lafayette, CO, USA), and transfected into the cells using
Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s instructions.
Radiation treatment. Cells in culture were irradiated with an irradiator (GE
3000) using a 137Cs source at a dose rate of 4.0 Gy/min. During irradiation, the
cultures were maintained in a container designed to mimic the conditions of the cell
culture incubator (5% CO2 and 95% air at 371C). For the GBM mice model, mice
were observed daily following tumor cell injection; 10 days after xenograft
transplantation, the healthy mice were randomized to radiation treatment group of
12 mice each. Radiation was delivered to the entire head of unanesthetized mice at
2 Gy each time. The mice were immobilized in a plastic restraint, through a single
right lateral beam from a 137Cs source. The remainder of the body was shielded with
a lead block. The radiation schedule was used during the course of this study: 2 Gy
M-W-F for 1 week (6 Gy in total) as established through preliminary studies. All mice
used for therapy response evaluations were euthanized at the time of reaching a
moribund condition.
Immunoprecipitation. Exponentially growing T98G, A172 or U251 cells were
irradiated with 10 Gy IR, then harvested at indicated time points and finally lysed in
1 ml of lysis buffer (0.5% (v/v) NP-40, 5 mM EDTA, 2 mM EGTA, 20 mM MOPS,
1 mM PMSF, 20 mM sodium pyrophosphate, 30 mM sodium fluoride, 40 mM
b-glycerophosphatase, 1 mM Na3VO3 and protease inhibitors) with caspase
inhibitor Z-VAD-FMK. Aliquots of 1 mg total protein were mixed with 4 mg of
monoclonal anti-DNA-PKcs antibody at 41C overnight. The bound proteins
were recovered by binding to 25ml of protein-A agarose (Sigma). The samples
were separated by 7.5% SDS-PAGE gel electrophoresis, then transferred
to nitrocellulose overnight and separated by SDS-PAGE and finally transferred to
nitrocellulose membranes. Proteins of interest were detected with specific
antibodies, followed with infrared dye 680- or 800-conjugated secondary
antibodies. Blots were scanned using an Odyssey infrared imaging system (Licor,
Lincoln, NE, USA), and proteins were quantitatively analyzed by the Odyssey
software (Licor).
DNA-PK kinase assay. Exponentially growing T98G, A172 or U251 cells
were treated with 10 Gy IR. After 30 min, the nuclear extracts were prepared as
described previously.7 Briefly, the cells were permeabilized, and the nuclei were
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extracted in lysis buffer containing 0.42 M NaCl and 1.5 mM MgCl2. DNA-PK activity
was analyzed using a DNA-PK activity assay kit30,31 according to the manufacturer’s
instructions (Promega Inc.).
Clonogenic assay. The clonogenic assay was adapted from Franken et al.14
Briefly, the IR-treated and -untreated control cells were harvested and 400 cells per
dish re-seeded in a 100 mm dish at an appropriate density to obtain approximately
50–100 colonies. Following 10–14 days of incubation, cells were fixed and stained
with crystal violet, and colonies containing at least 50 cells were scored.
Statistical analysis. The Kaplan–Meier estimator (GraphPad Prism 5,
GraphPad Software, La Jolla, CA, USA)32 was used to generate the survival curves
and to estimate the median survival values. Differences between survival curves were
compared using a log-rank test.33 Two-way categorical comparisons (i.e., PP6c
overexpression versus radiation treatment sensitivity, PP6c knocking-down versus
radiation treatment sensitivity) were carried out using Fisher’s exact test. Correlationship
of PP6c protein levels with patient survival time or cell survival fraction, and
correlationship between DNA-PK activity and cell survival fraction were analyzed by the
use of Spearson analysis (two-tailed) (GraphPad Prism, GraphPad Software). We also
used the Student’s t-test and Mann–WhitneyU-test when appropriate. All tests were two-
sided and Po0.05 was considered to be statistically significant.
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